Contents

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients (DRAGON)

December 30, 2020

Clinical trial

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study.

Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y, Zhang J, Dong F, Xu X, Weisberger A.

Acta Ophthalmol. 2021 May;99(3):e336-e345.
Full text | Metrics.

Main finding: Ranibizumab given monthly or PRN significantly improved visual acuity in Chinese patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

 

  • Purpose: To evaluate safety and efficacy of monthly and pro re nata regimes of intravitreal ranibizumab
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: ≥50 years, active CNV (PCV and non-PCV included) secondary to AMD, VA 20/32-20/320

 

  • n=334

 

Intervention:

 

Group 1: Intravitreal ranibizumab monthly from baseline to month 11, then PRN from month 12 to 23.
Group 2: Intravitreal ranibizumab monthly for 3 months then PRN up to month 23

Outcome Time point CNV type Monthly/PRN PRN
BCVA change 12 months All +12.3 +9.6
PCV +12.7 +9.4
non-PCV +12.1 +9.4
24 months All +11.3 +9.3
PCV +12.3 +9.7
non-PCV +10.6 +8.7

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed